Our integrative ML model uncovers hypoxia-centrosome crosstalk as a critical driver of LUAD progression. The hypoxia and centrosome score-related genes (HCSRGs) signature enables robust risk stratification and identifies actionable targets for precision oncology, providing a framework for personalized therapeutic strategies in LUAD.
Zheng et al. (Thu,) studied this question.